Abstract
Aggressive T-cell depletion, in vitro or in vivo, is a prerequisite for survival of haplo-identical stem cell transplantation. The classical T-cell-depleted transplant, immunomagnetically enriched CD34+ cells, is very safe with respect to graft-versus-host reactivity, but associated with very high transplant-related and relapse mortality with an overall probability of survival of only 20%. Protocols for T- and B-cell depletion were therefore developed, reasoning that transplantation of the majority of Natural Killer (NK) cells and the substantial dose of residual T-cells might improve survival, which was, in principle, confirmed. Anecdotal reports of frequent failure to achieve adequate T-cell depletion prompted review of the aggregate data for transplant quality at our center. The first observation is the relative paucity of combined CD3/CD19 depletion processes as PTCy protocols have made inroads, 13 depletions in 8 years. Median T- and B-cell log-depletion were −3.89 and −1.92, respectively; instead of, CD34+ cell recovery was generally high (median 92%), as was NK-cell recovery (median 52%). However, the process failed to yield satisfactory T- and B-cell depletion in two out of 13 preparations, of which one product could be rescued by a second round of depletion, at the expense of CD34+ cell recovery. In our hands, the process is thus insufficiently robust for routine clinical use. Assuming similar observations in other centers, this may explain implementation of alternative protocols, such as TCRαβ/CD19 depletion or transplantation of unmanipulated grafts with subsequent in vivo depletion.
Article PDF
Avoid common mistakes on your manuscript.
References
Aversa F, Martelli MM, Reisner Y. Use of stem cells from mismatched related donors. Curr Opin Hematol 1997;4;419–22.
Aversa F, Tabilio A, Velardi A, Terenzi A, Falzetti F, Carotti A, et al. Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option. Curr Stem Cell Res Ther 2007;2;105–12.
Klingebiel T, Handgretinger R, Lang P, Bader P, Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004;18;181–92.
Matsuda Y, Hara J, Osugi Y, Fujisaki H, Takai K, Ohta H, et al. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow Transplant 1998;21;355–60.
Martínez C, Urbano-Ispizua A, Rozman C, Marín P, Rovira M, Sierra J, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999;27;561–8.
Inoue H, Yasuda Y, Hattori K, Shimizu T, Matsumoto M, Yabe M, et al. The kinetics of immune reconstitution after cord blood transplantation and selected CD34+ stem cell transplantation in children: comparison with bone marrow transplantation. Int J Hematol 2003;77;399–407.
Roy DC, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, et al. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia 2020;34;1907–23.
Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, et al. Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001;27;777–83.
Martelli MF, Reisner Y. Haploidentical ‘megadose’ CD34+ cell transplants for patients with acute leukemia. Leukemia 2002;16;404–5.
Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77;1717–22.
Strauss LC, Trischmann TM, Rowley SD, Wiley JM, Civin CI. Selection of normal human hematopoietic stem cells for bone marrow transplantation using immunomagnetic microspheres and CD34 antibody. Am J Pediatr Hematol Oncol 1991;13;217–21.
Martín-Henao GA, Inglés-Esteve J, Cancelas JA, García J. Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS). Bone Marrow Transplant 1996;18;603–9.
Berger M, Faraci M, Saglio F, Giardino S, Ernestina Vassallo E, Prete A, et al. CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: results of a retrospective multicenter study. Pediatr Transplant 2021;25;e13909.
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 2014;20;382–6.
Larocca A, Piaggio G, Podestà M, Pitto A, Bruno B, Di Grazia C, et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006;91;935–40.
Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik HM, Eyrich M, et al. CD34+ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol 2018;180;90–9.
Marabelle A, Merlin E, Halle P, Paillard C, Berger M, Tchirkov A, et al. CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. Pediatr Blood Cancer 2011;56;134–42.
Handgretinger R, Lang P, Ihm K, Schumm M, Geiselhart A, Koscielniak E, et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 2002;29;731–6.
Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012;97;1523–31.
Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 2006;34;1746–52.
Bader P, Soerensen J, Jarisch A, Ponstingl E, Krenn T, Faber J, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol 2011;24;331–7.
Huenecke S, Bremm M, Cappel C, Esser R, Quaiser A, Bonig H, et al. Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. Transfusion 2016;56;2336–45.
Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood 2014;124;822–6.
Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion. Blood 2017;130;677–85.
Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol 2021;14;53.
Nagler A, Labopin M, Koc Y, Angelucci E, Tischer J, Arat M, et al. Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 2021;127;2507–14.
Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, et al. Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res 2021;27;843–51.
Bazarbachi A, Labopin M, Angelucci E, Gülbas Z, Ozdogu H, Arat M, et al. Haploidentical transplantation with post-transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biol Blood Marrow Transplant 2020;26;936–42.
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 2019;134;892–9.
Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica 2019;104;524–32.
Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, Tonn T. Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy 2011;13;449–58.
Klarmann D, Sireis W, Hogardt M, Kempf VA, Seifried E, Bonig H. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing. Cell Tissue Bank 2015;16;311–18.
Perseghin P, Gaipa G, Dassi M, Belotti D, Pogliani EM, Pioltelli P, et al. CD34+ stem cell recovery after positive selection of “overloaded” immunomagnetic columns. Stem Cells Dev 2005;14;740–3.
Panch SR, Reddy OL, Li K, Bikkani T, Rao A, Yarlagadda S, et al. Robust selections of various hematopoietic cell fractions on the CliniMACS plus instrument. Clin Hematol Int 2019;1;161–7.
Braakman E, Schuurhuis GJ, Preijers FW, Voermans C, Theunissen K, van Riet I, et al. Evaluation of ‘out-of-specification’ CliniMACS CD34-selection procedures of hematopoietic progenitor cell-apheresis products. Cytotherapy 2008;10;83–9.
EudraLex. The Rules Governing Medicinal Products in the European Union. Volume 4. Good Manufacturing Practice. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products. 2017, pp. 1–90. Available from: https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf (accessed July 15, 2021).
Glodek M, Liebowitz S, McCarthy R, McNally G, Oksanen C, Schultz T, et al. Process robustness—a PQRI white paper. Pharm Eng 2006;26;1–11.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: Anonymized raw data will be made available to interested readers upon reasonable request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Wiercinska, E., Seifried, E. & Bonig, H. CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust. Clin Hematol Int 3, 103–107 (2021). https://doi.org/10.2991/chi.k.210725.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.210725.001